Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy

뉴스 본문을 불러오고 있어요.

Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy | 웨이프 WAPE

Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy

기사 요약

관련 종목

댓글 —